| Stable angina
Norliqva vs Katerzia
Side-by-side clinical, coverage, and cost comparison for stable angina.Deep comparison between: Norliqva vs Katerzia with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsKaterzia has a higher rate of injection site reactions vs Norliqva based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Katerzia but not Norliqva, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Norliqva
Katerzia
At A Glance
Oral
Daily
Calcium channel blocker
Oral
Daily
Calcium channel blocker
Indications
- Hypertensive disease
- Stable angina
- Coronary heart disease
- Hypertensive disease
- Stable angina
- Angina Pectoris, Variant
- Coronary Artery Disease
Dosing
Hypertensive disease Adults: 5 mg orally once daily (max 10 mg); small, fragile, elderly, or hepatic insufficiency patients start at 2.5 mg once daily; pediatric patients (>=6 years): 2.5-5 mg orally once daily.
Stable angina 5-10 mg orally once daily; most patients require 10 mg for adequate effect.
Coronary heart disease 5-10 mg orally once daily; majority of patients in clinical studies required 10 mg.
Hypertensive disease (adults) 5 mg orally once daily (max 10 mg); start 2.5 mg in small, fragile, elderly patients, or those with hepatic insufficiency.
Hypertensive disease (pediatric, ages 6-17) 2.5-5 mg orally once daily; doses >5 mg have not been studied in pediatric patients.
Stable angina, Angina Pectoris, Variant 5-10 mg orally once daily; lower dose suggested in elderly and patients with hepatic insufficiency; most patients require 10 mg.
Coronary Artery Disease 5-10 mg orally once daily; majority of patients required 10 mg in clinical studies.
Contraindications
- Known sensitivity to amlodipine
- Known sensitivity to amlodipine
Adverse Reactions
Most common (>1%) Edema, dizziness, flushing, palpitation, fatigue, nausea.
Postmarketing Gynecomastia, jaundice, hepatic enzyme elevations, extrapyramidal disorder.
Most common (>1%) edema, dizziness, flushing, palpitation, fatigue, nausea, abdominal pain, somnolence
Postmarketing gynecomastia, jaundice, hepatic enzyme elevations, extrapyramidal disorder
Pharmacology
Amlodipine is a dihydropyridine calcium channel blocker that inhibits transmembrane influx of calcium ions into vascular smooth muscle and cardiac muscle, acting as a peripheral arterial vasodilator to reduce peripheral vascular resistance and blood pressure, and relieving angina by reducing myocardial oxygen demand and blocking coronary vasospasm.
Amlodipine is a dihydropyridine calcium channel blocker that inhibits transmembrane influx of calcium ions into vascular smooth muscle and cardiac muscle, causing peripheral arterial vasodilation, reduction in peripheral vascular resistance, and reduction in blood pressure.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Norliqva
- Covered on 5 commercial plans
- PA (6/12) · Step Therapy (0/12) · Qty limit (6/12)
Katerzia
- Covered on 5 commercial plans
- PA (6/12) · Step Therapy (1/12) · Qty limit (8/12)
UnitedHealthcare
Norliqva
- Covered on 4 commercial plans
- PA (4/8) · Step Therapy (0/8) · Qty limit (0/8)
Katerzia
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Norliqva
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (2/3) · Qty limit (2/3)
Katerzia
- Covered on 0 commercial plans
- PA (0/3) · Step Therapy (2/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Norliqva.
No savings programs available for Katerzia.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
NorliqvaView full Norliqva profile
KaterziaView full Katerzia profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.